Brought to you by

Wyeth-Ayerst pays $12.5mm for Neurogen's epileptic molecule
10 Feb 2015
Executive Summary
American Home Products' Wyeth-Ayerst division licensed worldwide rights to ADCI, a small molecule drug developed by Neurogen for treatment of epilepsy. The deal is worth about $12.5mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com